Sionna Therapeutics (NASDAQ:SION) Director Bruce Booth Sells 61,124 Shares

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Bruce Booth sold 61,124 shares of the stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $32.37, for a total transaction of $1,978,583.88. Following the completion of the transaction, the director directly owned 711,697 shares of the company’s stock, valued at approximately $23,037,631.89. This trade represents a 7.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Bruce Booth also recently made the following trade(s):

• On Thursday, October 16th, Bruce Booth sold 169,260 shares of Sionna Therapeutics stock. The shares were sold at an average price of $32.35, for a total transaction of $5,475,561.00.
• On Monday, October 20th, Bruce Booth sold 55,985 shares of Sionna Therapeutics stock. The shares were sold at an average price of $32.09, for a total transaction of $1,796,558.65.
• On Wednesday, October 15th, Bruce Booth sold 115,856 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.61, for a total transaction of $3,546,352.16.
• On Tuesday, October 14th, Bruce Booth sold 606 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $18,149.70.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.38, for a total transaction of $1,769,088.16.
• On Friday, October 10th, Bruce Booth sold 20,238 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.98, for a total transaction of $606,735.24.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $5,990.00.
• On Tuesday, September 30th, Bruce Booth sold 12,388 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.06, for a total transaction of $372,383.28.

Sionna Therapeutics Trading Up 0.8%

SION stock opened at $32.20 on Tuesday. The company’s 50 day simple moving average is $25.76 and its 200-day simple moving average is $18.76. Sionna Therapeutics, Inc. has a 12 month low of $7.26 and a 12 month high of $34.00.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.27.

Institutional Trading of Sionna Therapeutics

Institutional investors have recently made changes to their positions in the stock. Siren L.L.C. purchased a new stake in shares of Sionna Therapeutics during the 1st quarter valued at $3,400,000. Zimmer Partners LP purchased a new stake in shares of Sionna Therapeutics during the 1st quarter valued at $2,484,000. Goldman Sachs Group Inc. purchased a new stake in shares of Sionna Therapeutics during the 1st quarter valued at $667,000. Alyeska Investment Group L.P. purchased a new stake in shares of Sionna Therapeutics during the 1st quarter valued at $1,948,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Sionna Therapeutics during the 1st quarter valued at $676,000.

Analyst Upgrades and Downgrades

SION has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sionna Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Raymond James Financial initiated coverage on shares of Sionna Therapeutics in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating and a $45.00 target price for the company. Jones Trading initiated coverage on shares of Sionna Therapeutics in a research note on Monday, September 8th. They issued a “buy” rating and a $46.00 target price for the company. Finally, Royal Bank Of Canada initiated coverage on shares of Sionna Therapeutics in a research note on Wednesday, September 3rd. They issued a “sector perform” rating and a $22.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Sionna Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.